Strict glycemic control in diabetic dogs with closed-loop intraperitoneal insulin infusion algorithm designed for an artificial endocrine pancreas

Journal of Artificial Organs

Volumn 6, Issue 1, 2003, Pages 55-63

  Matsuo, Yasuto ^a   Shimoda, Seiya ^a   Sakakida, Michiharu ^a   Nishida, Kenro ^a   Sekigami, Taiji ^a   Ichimori, Shinji ^a   Ichinose, Kenshi ^a   Shichiri, Motoaki ^b   Araki, Eiichi ^a  

^a KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^b Kikuchi Med Doctors' Assoc Hosp   (Japan)

Author keywords

Artificial endocrine pancreas; Closed loop control system; Intraperitoneal insulin infusion algorithm; Regular insulin; Short acting insulin analog (insulin lispro)

Indexed keywords

ALLOXAN; GLUCOSE; INSULIN; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN;

ALGORITHM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ARTIFICIAL PANCREAS; COMPARTMENT MODEL; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE MODEL; DOG; DRUG ABSORPTION; GLUCOSE METABOLISM; HYPERINSULINISM; HYPOGLYCEMIA; INTERMETHOD COMPARISON; MATHEMATICAL MODEL; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; POSTPRANDIAL STATE; PRIORITY JOURNAL;

ALGORITHMS; ANIMALS; BLOOD GLUCOSE; DIABETES MELLITUS; DOGS; EATING; FEASIBILITY STUDIES; GLUCOSE; HYPOGLYCEMIC AGENTS; INFUSIONS, PARENTERAL; INSULIN; INSULIN INFUSION SYSTEMS; MODELS, THEORETICAL;

EID: 0037657817     PISSN: 14347229     EISSN: None     Source Type: Journal    
DOI: 10.1007/s100470300009     Document Type: Article

References (41)

1. The Diabetic Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986
2. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus - a randomized prospective 6-year study. Diabet Res Clin Pract 1995;28:103-117
3. United Kingdom Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylurea or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853
4. The Diabetic Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 2000;342:381-389
5. Shichiri M, Sakakida M, Nishida K, Shimoda S. Enhanced, simplified glucose sensors: long-term clinical application of wearable artificial endocrine pancreas. Artif Organs 1998;22:32-42
6. Shichiri M, Kawamori R, Yamasaki Y, Hakui N, Abe H. Wearable artificial endocrine pancreas with needle-type glucose sensor. Lancet 1982;ii:1129-1131
7. Shichiri M, Kawamori R, Hakui N, Yamasaki Y, Abe H. Closed-loop glycemic control with a wearable artificial endocrine pancreas - validations in daily insulin requirements to glycemic response. Diabetes 1984;33:1200-1202
8. Sakakida M, Ichinose K, Fukushima H, Nishida K, Kajiwara K, Hashiguchi Y, Taniguchi I, Shichiri M. Development of ferrocenemediated needle-type glucose sensor as a measure of true subcutaneous tissue glucose concentrations. Artif Organs Today 1992;2:145-158
9. Nishida K, Sakakida M, Ichinose K, Uemura T, Uehara M, Kajiwara K, Miyata T, Shichiri M, Ishihara K, Nakabayashi N. Development of a ferrocene-mediated needle-type glucose sensor covered with newly designed biocompatible membrane, 2methacryloyloxyethyl phosphorylcholine-co-n-butyl methacrylate. Med Prog Technol 1995;21:91-103
10. Ishihara K, Ueda T, Nakabayashi N. Preparation of phospholipid polymers and their properties as polymer hydrogel membranes. Polym J 1990;22:355-360
11. Ishihara K, Nakabayashi N, Nishida K, Sakakida M, Shichiri M. Designing biocompatible materials - the trick was to incorporate a phospholipid into one part of a methacrylate copolymer. The resulting material was used for an in vivo glucose sensor for diabetics. Chemtech 1993;1993:19-25
12. Shishko PI, Kovalev PA, Goncharov VG, Zajarny IU. Comparison of peripheral and portal (via the umbilical vein) routes of insulin infusion IDDM patients. Diabetes 1992;41:1042-1049
13. Canavan JP, Flecknell PA, New JP, Alberti KGMM, Home PD. The effect of portal and peripheral insulin delivery on carbohydrate and lipid metabolism in a miniature pig model of human IDDM. Diabetologia 1997;40:1125-1134
14. Kim JH, Lee YS, Kim SH, Lee SK, Lim MK, Kim HS. Does umbilical vein catheterization lead to portal venous thrombosis? Prospective US evaluation in 100 neonates. Radiology 2001;219:645-650
15. The Implantable Insulin Pump Trial Study Group. Long-term therapy of IDDM with an implantable insulin pump. Diabetes Care 1997;20:59-63
16. Schade DS, Eaton RP, Friedman NM, Spencer WJ, Standefer JC. Five-day programmed intraperitoneal insulin delivery in insulindependent diabetic man. J Clin Endocrinol Metab 1981;52:1165-1170
17. Wredling R, Adamson U, Lins PE, Backman L, Lundgren D. Experience of long-term intraperitoneal insulin treatment using a new percutaneous access device. Diabet Med 1991;8:597-600
18. Nomura M, Shichiri M, Kawamori R, Yamasaki Y, Iwama N, Abe H. A mathematical insulin secretion model and its validation in isolated rat pancreatic islets perifusion. Comput Biomed Res 1984;17:570-579
19. Shichiri M, Kawamori R. Optimized algorithms for closed-loop glycemic control systems. In: Albissor JBM, Schrezenmeir J, Lehmann L (eds) Computer systems for insulin adjustment in diabetes mellitus. Hedingen, Switzerland: Panscienta-Verlag, 1985;171-183
20. Kawamori R, Shichiri M, Goriya Y, Yamasaki Y, Shigeta Y, Abe H. Importance of insulin secretion based on the rate of change in blood glucose concentration in glucose tolerance, assessed by the artificial beta cell. Acta Endocrinol 1978;87:339-351
21. Goriya Y, Kawamori R, Shichiri M, Abe H. The development of an artificial beta cell system and its validation in depancreatized dogs - the physiological restoration of blood glucose homeostasis. Med Prog Technol 1979;6:99-108
22. Shichiri M, Kawamori R, Yamasaki Y. The development of artificial endocrine pancreas - from bedside-, wearable-type to implantable one. Med Prog Technol 1987;12:39-50
23. Hashiguchi Y, Sakakida M, Nishida K, Uemura T, Kajiwara K, Shichiri M. Development of a miniaturized glucose monitoring system by combining a needle-type glucose sensor with microdialysis sampling method. Diabetes Care 1994;17:387-396
24. 125I-labelled anti-(immunoglobulin G) antibodies. Biochem J 1975;145:607-616
25. Shimoda S, Nishida K, Sakakida M, Konno Y, Ichinose K, Uehara M, Nowak T, Shichiri M. Closed-loop subcutaneous insulin infusion algorithm with a short-acting insulin analog for long-term clinical application of a wearable artificial endocrine pancreas. Front Med Biol Eng 1997;8:197-211
26. Shah R, Miller M, Zhang Y, Bordeaux T, Torres K, Moran B, Lebel R. Glucose sensor control of an implantable insulin pump. Diabetes 2000;49(suppl 1):A125
27. Renard E, Costalat G, Moran B, Shah R, Zhang Y, Villegas D, Kolopp M, Lebel R, Bringer J. First combined implantations of a long-term IV glucose sensor and an intra-peritoneal insulin pump in diabetic patients. Diabetes 2001;50(suppl 2):A3
28. Schade DS, Eaton RP, Davis T, Akiya F, Phinney E, Kubica R, Vaughn EA, Day PW. The kinetics of peritoneal insulin absorption. Metabolism 1981;30:149-155
29. Zingg W, Rappaport AM, Leibel BS. Studies on transhepatic insulin absorption. Can J Physiol Pharmacol 1986;64:231-234
30. Scavini M, Pincelli A, Petrella G, Galimberti G, Zager PG, Torri M, Pozza G. Intraperitoneal insulin absorption after longterm intraperitoneal insulin therapy. Diabetes Care 1995:18:56-59
31. Selam JL. Implantable insulin pumps. Lancet 1999;354:178-179
32. Thompson JS, Duckworth WC. Insulin pumps and glucose regulation. World J Surg 2001;25:523-526
33. Wan CK, Giacca A, Matsuhisa M, El-Bahrani B, Lam L, Rodgers C, Shi ZQ. Increased responses of glucagon and glucose production to hypoglycemia with intraperitoneal versus subcutaneous insulin treatment. Metabolism 2000;49:984-989
34. Schade DS, Eaton RP. Insulin delivery: How, when, and where. N Engl J Med 1985;312:1120-1121
35. Micossi P, Cristallo M, Librenti MC, Petrella G, Galimberti G, Melandri M, Monti L, Spotti D, Scavini M, Di Carlo V, Pozza G. Free-insulin profiles after intraperitoneal, intramuscular, and subcutaneous insulin administration. Diabetes Care 1986;9:575-578
36. Torri M, Scavini M, Dozio N, Petrella G, Galimberti G, Pozza G. Pharmacokinetics of insulin analogue Lys (B28) Pro (B29) following intraperitoneal administration. Diabetes 1995;44(suppl 1):130A
37. Lougheed WD, Zinman B, Strack TR, Janis LJ, Weymouth AB, Bernstein EA, Korbas AM, Frank BH. Stability of insulin lispro in insulin infusion systems. Diabetes Care 1997;20:1061-1065
38. DiMarchi RD, Chance RE, Long HB, Shields JE, Slieker LJ. Preparation of an insulin with improved pharmacokinetics relative to human insulin through consideration of structural homology with insulin-like growth factor 1. Horm Res 1994;41(suppl 2):93-96
39. Kraegen EW, Chisholm DJ. Insulin responses to varying profiles of subcutaneous insulin infusion: kinetic modelling studies. Diabetologia 1984;26:208-213
40. Albisser AM, Leibel BS, Ewart TG, Davidovac Z, Botz CK, Zingg W. An artificial endocrine pancreas. Diabetes 1974;23:389-396
41. Leblanc H, Chauvet D, Lombrail P, Robert JJ. Glycemic control with closed-loop intraperitoneal insulin in type I diabetes. Diabetes Care 1986:9:124-128